HER2阳性早期乳腺癌循环肿瘤细胞的HER2表型：前瞻性随机III期试验的转化研究项目

数据集获取（Figshare）

• 源站标题：The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
• DOI：10.1371/journal.pone.0173593
• 发布日期：2017-06-06
• 文件数：2 个
• 文件总体积：637.46 KB
• 源站页面：https://plos.figshare.com/articles/dataset/The_HER2_phenotype_of_circulating_tumor_cells_in_HER2-positive_early_breast_cancer_A_translational_research_project_of_a_prospective_randomized_phase_III_trial/5082874

命令行下载

curl -L -o "S1 File.pdf" "https://ndownloader.figshare.com/files/8626141"
curl -L -o "S2 File.xlsx" "https://ndownloader.figshare.com/files/8626153"

文件清单

• S1 File.pdf（584.37 KB）
• S2 File.xlsx（53.09 KB）

文件总体积 637.46 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
HER2 is one of the predominant therapeutic targets in breast cancer. The metastatic selection process may lead to discrepancies between the HER2 status of the primary tumor and circulating tumor cells (CTCs). This study analyzed the HER2 status of CTCs in patients with HER2-positive primary breast cancer at the time of diagnosis. Aim of the study was to assess potential discordance of HER2 status between primary tumor and CTCs, as this may have important implications for the use of HER2-targeted therapy.
Methods
The number and HER2 status of CTCs out of 30ml peripheral blood were assessed in 642 patients using the CellSearch System (Janssen Diagnostics, USA). The cutoff for CTC positivity was the presence of at least 1 CTC, and the cutoff for HER2 positivity of CTCs was the presence of at least 1 CTC with a strong HER2 staining.
Results
258 (40.2%) of the 642 patients were positive for CTCs (median 2; range 1–1,689). 149 (57.8%) of these 258 patients had at least 1 CTC with strong HER2 staining. The presence of HER2-positive CTCs was not associated with tumor size (p = 0.335), histopathological grading (p = 0.976), hormone receptor status (ER: p = 0.626, PR: p = 0.263) or axillary lymph node involvement (p = 0.430). Overall, 83 (32.2%) of the CTC-positive patients exclusively had CTCs with strong HER2 staining, whereas 31 (12.0%) had only CTCs with negative HER2 staining. Within-sample variation in the HER2 status of CTCs was found in 86 (57.8%) of the 149 patients with more than 1 CTC.
Conclusion
This study demonstrated that discordance between the HER2 expression of CTCs and that of the primary tumor frequently occurs in early breast cancer. Future follow-up evaluation will assess whether this discrepancy may contribute to trastuzumab resistance.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0173593（source: https://plos.figshare.com/articles/dataset/The_HER2_phenotype_of_circulating_tumor_cells_in_HER2-positive_early_breast_cancer_A_translational_research_project_of_a_prospective_randomized_phase_III_trial/5082874）。